American Century Companies Inc. Purchases 15,472 Shares of Aerie Pharmaceuticals Inc (AERI)

American Century Companies Inc. boosted its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 20.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 89,429 shares of the company’s stock after purchasing an additional 15,472 shares during the quarter. American Century Companies Inc. owned about 0.20% of Aerie Pharmaceuticals worth $3,228,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Vanguard Group Inc increased its stake in Aerie Pharmaceuticals by 12.7% during the 3rd quarter. Vanguard Group Inc now owns 3,887,580 shares of the company’s stock valued at $239,281,000 after buying an additional 436,964 shares during the period. Vanguard Group Inc. increased its stake in Aerie Pharmaceuticals by 12.7% during the 3rd quarter. Vanguard Group Inc. now owns 3,887,580 shares of the company’s stock valued at $239,281,000 after buying an additional 436,964 shares during the period. BlackRock Inc. increased its stake in Aerie Pharmaceuticals by 2.7% during the 4th quarter. BlackRock Inc. now owns 3,208,945 shares of the company’s stock valued at $115,843,000 after buying an additional 84,605 shares during the period. Foresite Capital Management III LLC increased its stake in Aerie Pharmaceuticals by 14.2% during the 4th quarter. Foresite Capital Management III LLC now owns 1,950,477 shares of the company’s stock valued at $70,412,000 after buying an additional 242,431 shares during the period. Finally, Foresite Capital Management II LLC increased its stake in Aerie Pharmaceuticals by 14.2% during the 4th quarter. Foresite Capital Management II LLC now owns 1,672,714 shares of the company’s stock valued at $60,385,000 after buying an additional 207,965 shares during the period.

AERI has been the topic of several research analyst reports. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Monday, February 25th. ValuEngine cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Canaccord Genuity set a $65.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 20th. Mizuho reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, January 18th. Finally, Oppenheimer set a $64.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $76.50.

Shares of AERI opened at $41.33 on Tuesday. The company has a market capitalization of $1.92 billion, a PE ratio of -8.89 and a beta of 0.96. Aerie Pharmaceuticals Inc has a 12-month low of $32.18 and a 12-month high of $74.75.

In other news, insider Casey C. Kopczynski sold 11,000 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $46.17, for a total value of $507,870.00. Following the transaction, the insider now directly owns 97,243 shares of the company’s stock, valued at $4,489,709.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.53% of the company’s stock.

TRADEMARK VIOLATION WARNING: “American Century Companies Inc. Purchases 15,472 Shares of Aerie Pharmaceuticals Inc (AERI)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://transcriptdaily.com/2019/04/16/american-century-companies-inc-purchases-15472-shares-of-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: Growth and Income Funds

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.